Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$64.67M
Enterprise ValueAU$58.05M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding340,368,300
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Pipeline: Colostat ScreeningRhythm's singular focus on Colostat creates a clear, capital-efficient commercial path in colorectal screening. Targeting population screening and clinical pathways aligns with durable preventive care trends and allows concentrated R&D and go-to-market efforts, improving the odds of scalable adoption if clinical/regulatory milestones are met.
High Gross Margin ProfileA high gross margin indicates attractive unit economics typical of diagnostics, which can support profitability once fixed costs and development expenses are absorbed. This structural margin advantage enables leverage from volume, improving long-term margin sustainability if Colostat achieves commercial uptake.
Improving Free Cash Flow TrendAn improving free cash flow trend, even from negative levels, signals progress toward better cash conversion and operational discipline. Over months, continued improvement reduces reliance on external funding, extends runway for commercialization activities, and strengthens the firm's ability to invest in scale-up when revenues rise.
Bears Say
Steep Recent Revenue DeclineA 42.87% revenue drop reflects weakening commercial traction or timing setbacks in uptake. Persistent revenue volatility hampers the company’s ability to cover fixed costs, slows scale-up of diagnostics distribution, increases funding needs, and materially delays the transition to self-sustaining operations.
Persistent UnprofitabilityChronic negative net, EBIT and EBITDA margins indicate the business is not yet generating operating profits and remains reliant on external capital. Over a multi-month horizon, continued losses constrain reinvestment, elevate refinancing risk, and reduce flexibility to scale commercialization without dilution or onerous financing terms.
Elevated Financial LeverageA debt-to-equity ratio of 1.68 signals meaningful leverage for a clinical-stage diagnostics firm. Elevated debt raises fixed obligations, limits strategic flexibility, and can restrict R&D and commercialization spending if revenues underperform, increasing the risk of covenant pressure or the need for dilutive capital raises.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$64.67M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 140 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 340,368,300 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHY Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-476.27%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―